O	0	1	1	1	LS	B-LST
O	1	2	.	.	.	O

O	3	15	Introduction	Introduction	NN	B-NP

O	16	21	Phase	Phase	NN	B-NP
O	22	23	I	I	CD	I-NP
O	24	32	clinical	clinical	JJ	I-NP
O	33	39	trials	trial	NNS	I-NP
O	40	42	of	of	IN	B-PP
O	43	46	new	new	JJ	B-NP
O	47	57	anticancer	anticancer	JJ	I-NP
O	58	64	agents	agent	NNS	I-NP
O	65	69	have	have	VBP	B-VP
O	70	74	been	be	VBN	I-VP
O	75	83	commonly	commonly	RB	I-VP
O	84	93	conducted	conduct	VBN	I-VP
O	94	99	using	use	VBG	I-VP
O	100	103	the	the	DT	B-NP
O	104	110	method	method	NN	I-NP
O	111	113	of	of	IN	B-PP
O	114	122	modified	modify	VBN	B-NP
O	123	132	Fibonacci	Fibonacci	NNP	I-NP
O	133	134	[	[	(	O
O	134	135	1	1	CD	B-NP
O	135	136	]	]	)	O
O	136	137	.	.	.	O

O	138	140	In	In	IN	B-PP
O	141	146	brief	brief	NN	B-NP
O	146	147	,	,	,	O
O	148	149	3	3	CD	B-NP
O	150	158	patients	patient	NNS	I-NP
O	159	162	are	be	VBP	B-VP
O	163	170	treated	treat	VBN	I-VP
O	171	173	at	at	IN	B-PP
O	174	175	a	a	DT	B-NP
O	176	184	starting	start	VBG	I-NP
O	185	189	dose	dose	NN	I-NP
O	190	195	which	which	WDT	B-NP
O	196	198	is	be	VBZ	B-VP
O	199	208	typically	typically	RB	B-ADVP
O	209	212	one	one	CD	B-NP
O	213	218	tenth	tenth	NN	I-NP
O	219	221	of	of	IN	B-PP
O	222	225	the	the	DT	B-NP
O	226	230	dose	dose	NN	I-NP
O	231	235	that	that	WDT	B-NP
O	236	238	is	be	VBZ	B-VP
O	239	245	lethal	lethal	JJ	B-ADJP
O	246	248	to	to	TO	B-PP
O	249	251	10	10	CD	B-NP
O	251	252	%	%	NN	I-NP
O	253	255	of	of	IN	B-PP
O	256	263	animals	animal	NNS	B-NP
O	264	271	defined	define	VBN	B-VP
O	272	274	in	in	IN	B-PP
O	275	286	preclinical	preclinical	JJ	B-NP
O	287	294	studies	study	NNS	I-NP
O	294	295	.	.	.	O

O	296	298	If	If	IN	B-SBAR
O	299	303	none	none	NN	B-NP
O	304	306	of	of	IN	B-PP
O	307	310	the	the	DT	B-NP
O	311	312	3	3	CD	I-NP
O	313	321	patients	patient	NNS	I-NP
O	322	333	experiences	experience	NNS	I-NP
O	334	337	DLT	DLT	NN	I-NP
O	337	338	,	,	,	O
O	339	343	then	then	RB	B-ADVP
O	344	347	the	the	DT	B-NP
O	348	352	next	next	JJ	I-NP
O	353	354	3	3	CD	I-NP
O	355	363	patients	patient	NNS	I-NP
O	364	368	will	will	MD	B-VP
O	369	371	be	be	VB	I-VP
O	372	379	treated	treat	VBN	I-VP
O	380	382	at	at	IN	B-PP
O	383	386	the	the	DT	B-NP
O	387	391	next	next	JJ	I-NP
O	392	398	higher	high	JJR	I-NP
O	399	403	dose	dose	NN	I-NP
O	403	404	.	.	.	O

O	405	407	If	If	IN	B-SBAR
O	408	411	DLT	DLT	NN	B-NP
O	412	414	is	be	VBZ	B-VP
O	415	423	observed	observe	VBN	I-VP
O	423	424	,	,	,	O
O	425	435	additional	additional	JJ	B-NP
O	436	444	patients	patient	NNS	I-NP
O	445	449	will	will	MD	B-VP
O	450	452	be	be	VB	I-VP
O	453	460	treated	treat	VBN	I-VP
O	461	463	at	at	IN	B-PP
O	464	467	the	the	DT	B-NP
O	468	472	same	same	JJ	I-NP
O	473	475	or	or	CC	I-NP
O	476	481	lower	low	JJR	I-NP
O	482	486	dose	dose	NN	I-NP
O	487	492	level	level	NN	I-NP
O	493	495	to	to	TO	B-VP
O	496	505	determine	determine	VB	I-VP
O	506	509	MTD	MTD	NN	B-NP
O	510	519	according	accord	VBG	B-PP
O	520	522	to	to	TO	B-PP
O	523	524	a	a	DT	B-NP
O	525	538	predetermined	predetermine	VBN	I-NP
O	539	545	schema	schema	NN	I-NP
O	545	546	.	.	.	O

O	547	550	The	The	DT	B-NP
O	551	554	MTD	MTD	NN	I-NP
O	555	557	is	be	VBZ	B-VP
O	558	565	defined	define	VBN	I-VP
O	566	568	as	as	IN	B-PP
O	569	572	the	the	DT	B-NP
O	573	580	highest	high	JJS	I-NP
O	581	585	dose	dose	NN	I-NP
O	586	593	reached	reach	VBN	B-VP
O	594	597	for	for	IN	B-PP
O	598	603	which	which	WDT	B-NP
O	604	607	the	the	DT	B-NP
O	608	617	incidence	incidence	NN	I-NP
O	618	620	of	of	IN	B-PP
O	621	624	DLT	DLT	NN	B-NP
O	625	631	occurs	occur	VBZ	B-VP
O	632	634	in	in	IN	B-PP
O	635	639	less	less	JJR	B-NP
O	640	644	than	than	IN	I-NP
O	645	647	33	33	CD	I-NP
O	647	648	%	%	NN	I-NP
O	649	651	of	of	IN	B-PP
O	652	655	the	the	DT	B-NP
O	656	664	subjects	subject	NNS	I-NP
O	664	665	.	.	.	O

O	666	675	Typically	Typically	RB	B-ADVP
O	675	676	,	,	,	O
O	677	689	intrapatient	intrapatient	JJ	B-NP
O	690	694	dose	dose	NN	I-NP
O	695	705	escalation	escalation	NN	I-NP
O	706	708	is	be	VBZ	B-VP
O	709	712	not	not	RB	I-VP
O	713	720	allowed	allow	VBN	I-VP
O	720	721	.	.	.	O

O	722	727	There	There	EX	B-NP
O	728	731	are	be	VBP	B-VP
O	732	739	several	several	JJ	B-NP
O	740	752	shortcomings	shortcoming	NNS	I-NP
O	753	763	associated	associate	VBN	B-VP
O	764	768	with	with	IN	B-PP
O	769	772	the	the	DT	B-NP
O	773	781	modified	modify	VBN	I-NP
O	781	782	-	-	HYPH	I-NP
O	782	791	Fibonacci	Fibonacci	NN	I-NP
O	792	798	design	design	NN	I-NP
O	798	799	.	.	.	O

O	800	802	It	It	PRP	B-NP
O	803	806	has	have	VBZ	B-VP
O	807	811	long	long	RB	I-VP
O	812	816	been	be	VBN	I-VP
O	817	827	recognized	recognize	VBN	I-VP
O	828	832	that	that	IN	B-SBAR
O	833	834	a	a	DT	B-NP
O	835	846	substantial	substantial	JJ	I-NP
O	847	853	number	number	NN	I-NP
O	854	856	of	of	IN	B-PP
O	857	865	patients	patient	NNS	B-NP
O	866	869	are	be	VBP	B-VP
O	870	876	likely	likely	JJ	B-ADJP
O	877	879	to	to	TO	B-VP
O	880	882	be	be	VB	I-VP
O	883	890	treated	treat	VBN	I-VP
O	891	893	at	at	IN	B-PP
O	894	908	subtherapeutic	subtherapeutic	JJ	B-NP
O	909	914	doses	dose	NNS	I-NP
O	915	916	[	[	(	B-NP
O	916	917	2	2	CD	I-NP
O	917	918	,	,	,	I-NP
O	919	920	3	3	CD	I-NP
O	920	921	]	]	)	O
O	921	922	.	.	.	O

O	923	927	This	This	DT	B-NP
O	928	930	is	be	VBZ	B-VP
O	931	943	particularly	particularly	RB	B-ADJP
O	944	948	true	true	JJ	I-ADJP
O	949	952	for	for	IN	B-PP
O	953	958	drugs	drug	NNS	B-NP
O	959	963	with	with	IN	B-PP
O	964	973	potential	potential	JJ	B-NP
O	974	984	anticancer	anticancer	JJ	I-NP
O	985	993	activity	activity	NN	I-NP
O	993	994	.	.	.	O

O	995	1000	Since	Since	IN	B-SBAR
O	1001	1004	the	the	DT	B-NP
O	1005	1012	primary	primary	JJ	I-NP
O	1013	1020	purpose	purpose	NN	I-NP
O	1021	1023	of	of	IN	B-PP
O	1024	1029	phase	phase	NN	B-NP
O	1030	1031	I	I	CD	I-NP
O	1032	1038	trials	trial	NNS	I-NP
O	1039	1041	is	be	VBZ	B-VP
O	1042	1044	to	to	TO	B-VP
O	1045	1054	determine	determine	VB	I-VP
O	1055	1058	DLT	DLT	NN	B-NP
O	1059	1062	and	and	CC	I-NP
O	1063	1066	MTD	MTD	NN	I-NP
O	1066	1067	,	,	,	O
O	1068	1071	the	the	DT	B-NP
O	1072	1080	efficacy	efficacy	NN	I-NP
O	1081	1083	of	of	IN	B-PP
O	1084	1087	the	the	DT	B-NP
O	1088	1092	drug	drug	NN	I-NP
O	1093	1096	may	may	MD	B-VP
O	1097	1100	not	not	RB	I-VP
O	1101	1103	be	be	VB	I-VP
O	1104	1111	evident	evident	JJ	B-ADJP
O	1112	1115	for	for	IN	B-PP
O	1116	1123	certain	certain	JJ	B-NP
B-Cancer	1124	1129	tumor	tumor	NN	I-NP
O	1130	1135	types	type	NNS	I-NP
O	1136	1138	as	as	IN	B-SBAR
O	1139	1144	there	there	EX	B-NP
O	1145	1148	are	be	VBP	B-VP
O	1149	1153	only	only	RB	B-NP
O	1154	1155	a	a	DT	I-NP
O	1156	1161	small	small	JJ	I-NP
O	1162	1168	number	number	NN	I-NP
O	1169	1171	of	of	IN	B-PP
O	1172	1180	patients	patient	NNS	B-NP
O	1181	1189	enrolled	enrol	VBN	B-VP
O	1190	1194	into	into	IN	B-PP
O	1195	1198	the	the	DT	B-NP
O	1199	1204	trial	trial	NN	I-NP
O	1204	1205	.	.	.	O

O	1206	1217	Furthermore	Furthermore	RB	B-ADVP
O	1217	1218	,	,	,	O
O	1219	1222	the	the	DT	B-NP
O	1223	1231	modified	modify	VBN	I-NP
O	1231	1232	-	-	HYPH	I-NP
O	1232	1241	Fibonacci	Fibonacci	NN	I-NP
O	1242	1248	design	design	NN	I-NP
O	1249	1253	does	do	VBZ	B-VP
O	1254	1257	not	not	RB	I-VP
O	1258	1262	take	take	VB	I-VP
O	1263	1267	into	into	IN	B-PP
O	1268	1275	account	account	NN	B-NP
O	1276	1286	individual	individual	JJ	I-NP
O	1287	1297	variations	variation	NNS	I-NP
O	1298	1300	in	in	IN	B-PP
O	1301	1312	therapeutic	therapeutic	JJ	B-NP
O	1313	1316	and	and	CC	I-NP
O	1317	1328	toxicologic	toxicologic	JJ	I-NP
O	1329	1338	responses	response	NNS	I-NP
O	1339	1342	due	due	JJ	B-ADJP
O	1343	1345	to	to	TO	B-PP
O	1346	1353	genomic	genomic	JJ	B-NP
O	1354	1367	polymorphisms	polymorphism	NNS	I-NP
O	1368	1369	[	[	(	O
O	1369	1370	4	4	CD	B-NP
O	1370	1371	,	,	,	I-NP
O	1372	1373	5	5	CD	I-NP
O	1373	1374	]	]	)	O
O	1374	1375	.	.	.	O

O	1376	1378	In	In	IN	B-PP
O	1379	1387	addition	addition	NN	B-NP
O	1387	1388	,	,	,	O
O	1389	1394	since	since	IN	B-SBAR
O	1395	1400	there	there	EX	B-NP
O	1401	1403	is	be	VBZ	B-VP
O	1404	1405	a	a	DT	B-NP
O	1406	1411	limit	limit	NN	I-NP
O	1412	1414	of	of	IN	B-PP
O	1415	1416	3	3	CD	B-NP
O	1417	1425	subjects	subject	NNS	I-NP
O	1426	1433	allowed	allow	VBN	B-VP
O	1434	1437	for	for	IN	B-PP
O	1438	1442	each	each	DT	B-NP
O	1443	1449	cohort	cohort	NN	I-NP
O	1449	1450	,	,	,	O
O	1451	1452	a	a	DT	B-NP
O	1453	1460	waiting	wait	VBG	I-NP
O	1461	1467	period	period	NN	I-NP
O	1468	1470	of	of	IN	B-PP
O	1471	1473	up	up	IN	B-NP
O	1474	1476	to	to	TO	I-NP
O	1477	1481	four	four	CD	I-NP
O	1482	1487	weeks	week	NNS	I-NP
O	1488	1490	is	be	VBZ	B-VP
O	1491	1499	commonly	commonly	RB	I-VP
O	1500	1508	required	require	VBN	I-VP
O	1509	1515	before	before	IN	B-PP
O	1516	1526	enrollment	enrollment	NN	B-NP
O	1527	1529	of	of	IN	B-PP
O	1530	1533	the	the	DT	B-NP
O	1534	1538	next	next	JJ	I-NP
O	1539	1545	cohort	cohort	NN	I-NP
O	1546	1548	of	of	IN	B-PP
O	1549	1557	subjects	subject	NNS	B-NP
O	1557	1558	.	.	.	O

O	1559	1563	This	This	DT	B-NP
O	1564	1570	latter	latter	JJ	I-NP
O	1571	1582	requirement	requirement	NN	I-NP
O	1583	1590	creates	create	VBZ	B-VP
O	1591	1598	anxiety	anxiety	NN	B-NP
O	1599	1601	of	of	IN	B-PP
O	1602	1609	waiting	wait	VBG	B-VP
O	1610	1613	for	for	IN	B-PP
O	1614	1622	eligible	eligible	JJ	B-NP
O	1623	1631	patients	patient	NNS	I-NP
O	1631	1632	.	.	.	O

O	1633	1640	Several	Several	JJ	B-NP
O	1641	1652	alternative	alternative	JJ	I-NP
O	1653	1658	phase	phase	NN	I-NP
O	1659	1660	I	I	CD	B-NP
O	1661	1668	designs	design	NNS	I-NP
O	1669	1673	have	have	VBP	B-VP
O	1674	1678	been	be	VBN	I-VP
O	1679	1687	proposed	propose	VBN	I-VP
O	1688	1693	which	which	WDT	B-NP
O	1694	1699	limit	limit	VBP	B-VP
O	1700	1703	the	the	DT	B-NP
O	1704	1710	number	number	NN	I-NP
O	1711	1713	of	of	IN	B-PP
O	1714	1722	patients	patient	NNS	B-NP
O	1723	1730	accrued	accrue	VBN	B-VP
O	1731	1733	at	at	IN	B-PP
O	1734	1738	each	each	DT	B-NP
O	1739	1743	dose	dose	NN	I-NP
O	1744	1749	level	level	NN	I-NP
O	1750	1753	and	and	CC	O
O	1754	1764	accelerate	accelerate	VB	B-VP
O	1765	1768	the	the	DT	B-NP
O	1769	1773	dose	dose	NN	I-NP
O	1774	1784	escalation	escalation	NN	I-NP
O	1785	1792	process	process	NN	I-NP
O	1793	1794	[	[	(	B-NP
O	1794	1795	1	1	CD	I-NP
O	1795	1796	,	,	,	I-NP
O	1797	1798	6	6	CD	I-NP
O	1798	1799	]	]	)	O
O	1799	1800	.	.	.	O

O	1801	1806	There	There	EX	B-NP
O	1807	1810	has	have	VBZ	B-VP
O	1811	1815	also	also	RB	I-VP
O	1816	1820	been	be	VBN	I-VP
O	1821	1823	an	an	DT	B-NP
O	1824	1832	increase	increase	NN	I-NP
O	1833	1835	in	in	IN	B-PP
O	1836	1839	the	the	DT	B-NP
O	1840	1846	number	number	NN	I-NP
O	1847	1849	of	of	IN	B-PP
O	1850	1858	clinical	clinical	JJ	B-NP
O	1859	1865	trials	trial	NNS	I-NP
O	1866	1870	that	that	WDT	B-NP
O	1871	1878	include	include	VBP	B-VP
O	1879	1880	a	a	DT	B-NP
O	1881	1890	component	component	NN	I-NP
O	1891	1893	of	of	IN	B-PP
O	1894	1906	intrapatient	intrapatient	JJ	B-NP
O	1907	1911	dose	dose	NN	I-NP
O	1912	1922	escalation	escalation	NN	I-NP
O	1923	1931	although	although	IN	B-SBAR
O	1932	1934	no	no	DT	B-NP
O	1935	1941	formal	formal	JJ	I-NP
O	1942	1952	validation	validation	NN	I-NP
O	1953	1957	with	with	IN	B-PP
O	1958	1961	the	the	DT	B-NP
O	1962	1970	modified	modify	VBN	I-NP
O	1970	1971	-	-	HYPH	I-NP
O	1971	1980	Fibonacci	Fibonacci	NNP	I-NP
O	1981	1989	approach	approach	NN	I-NP
O	1990	1993	has	have	VBZ	B-VP
O	1994	1998	been	be	VBN	I-VP
O	1999	2007	reported	report	VBN	I-VP
O	2008	2009	[	[	(	O
O	2009	2010	7	7	CD	B-NP
O	2010	2011	-	-	HYPH	I-NP
O	2011	2012	9	9	CD	I-NP
O	2012	2013	]	]	)	O
O	2013	2014	.	.	.	O

O	2015	2017	We	We	PRP	B-NP
O	2018	2022	have	have	VBP	B-VP
O	2023	2032	pioneered	pioneer	VBN	I-VP
O	2033	2034	a	a	DT	B-NP
O	2035	2045	population	population	NN	I-NP
O	2045	2046	-	-	HYPH	O
O	2046	2051	based	base	VBN	B-VP
O	2052	2058	design	design	NN	B-NP
O	2059	2061	to	to	TO	B-VP
O	2062	2070	maximize	maximize	VB	I-VP
O	2071	2082	therapeutic	therapeutic	JJ	B-NP
O	2083	2091	efficacy	efficacy	NN	I-NP
O	2091	2092	,	,	,	O
O	2093	2095	to	to	TO	B-VP
O	2096	2103	provide	provide	VB	I-VP
O	2104	2115	preliminary	preliminary	JJ	B-NP
O	2116	2124	efficacy	efficacy	NN	I-NP
O	2125	2136	information	information	NN	I-NP
O	2137	2140	and	and	CC	O
O	2141	2143	to	to	TO	B-VP
O	2144	2149	allow	allow	VB	I-VP
O	2150	2160	derivation	derivation	NN	B-NP
O	2161	2163	of	of	IN	B-PP
O	2164	2165	a	a	DT	B-NP
O	2166	2170	pMTD	pMTD	NN	I-NP
O	2171	2174	for	for	IN	B-PP
O	2175	2185	subsequent	subsequent	JJ	B-NP
O	2186	2191	phase	phase	NN	I-NP
O	2192	2194	II	II	CD	B-NP
O	2195	2201	trials	trial	NNS	I-NP
O	2201	2202	.	.	.	O

O	2203	2213	Irinotecan	Irinotecan	NN	B-NP
O	2214	2217	and	and	CC	I-NP
O	2218	2227	cisplatin	cisplatin	NN	I-NP
O	2228	2232	have	have	VBP	B-VP
O	2233	2237	been	be	VBN	I-VP
O	2238	2243	shown	show	VBN	I-VP
O	2244	2246	to	to	TO	I-VP
O	2247	2251	have	have	VB	I-VP
O	2252	2261	promising	promising	JJ	B-NP
O	2262	2270	efficacy	efficacy	NN	I-NP
O	2271	2273	in	in	IN	B-PP
O	2274	2282	patients	patient	NNS	B-NP
O	2283	2287	with	with	IN	B-PP
B-Cancer	2288	2293	small	small	JJ	B-NP
I-Cancer	2293	2294	-	-	HYPH	I-NP
I-Cancer	2294	2298	cell	cell	NN	I-NP
I-Cancer	2299	2303	lung	lung	NN	I-NP
I-Cancer	2304	2310	cancer	cancer	NN	I-NP
O	2311	2313	in	in	IN	B-PP
O	2314	2319	phase	phase	NN	B-NP
O	2320	2323	III	III	CD	I-NP
O	2324	2329	trial	trial	NN	I-NP
O	2330	2335	where	where	WRB	B-ADVP
O	2336	2346	irinotecan	irinotecan	NN	B-NP
O	2347	2350	was	be	VBD	B-VP
O	2351	2356	given	give	VBN	I-VP
O	2357	2359	on	on	IN	B-PP
O	2360	2361	a	a	DT	B-NP
O	2362	2368	weekly	weekly	JJ	I-NP
O	2369	2377	schedule	schedule	NN	I-NP
O	2378	2379	[	[	(	O
O	2379	2381	10	10	CD	B-NP
O	2381	2382	]	]	)	O
O	2382	2383	.	.	.	O

O	2384	2386	We	We	PRP	B-NP
O	2387	2393	wished	wish	VBD	B-VP
O	2394	2396	to	to	TO	I-VP
O	2397	2404	perform	perform	VB	I-VP
O	2405	2406	a	a	DT	B-NP
O	2407	2417	population	population	NN	I-NP
O	2417	2418	-	-	HYPH	O
O	2418	2423	based	base	VBN	B-VP
O	2424	2429	phase	phase	NN	B-NP
O	2430	2431	I	I	CD	I-NP
O	2432	2437	trial	trial	NN	I-NP
O	2438	2440	of	of	IN	B-PP
O	2441	2451	irinotecan	irinotecan	NN	B-NP
O	2451	2452	,	,	,	O
O	2453	2458	given	give	VBN	B-PP
O	2459	2464	every	every	DT	B-NP
O	2465	2466	3	3	CD	I-NP
O	2467	2472	weeks	week	NNS	I-NP
O	2472	2473	,	,	,	O
O	2474	2477	and	and	CC	O
O	2478	2489	carboplatin	carboplatin	NN	B-NP
O	2489	2490	,	,	,	O
O	2491	2492	a	a	DT	B-NP
O	2493	2503	platinated	platinate	VBN	I-NP
O	2504	2514	anticancer	anticancer	JJ	I-NP
O	2515	2519	drug	drug	NN	I-NP
O	2520	2525	which	which	WDT	B-NP
O	2526	2528	is	be	VBZ	B-VP
O	2529	2538	generally	generally	RB	B-ADVP
O	2539	2545	better	well	RBR	B-ADJP
O	2546	2555	tolerated	tolerate	VBN	I-ADJP
O	2556	2560	than	than	IN	B-PP
O	2561	2564	its	its	PRP$	B-NP
O	2565	2574	cisplatin	cisplatin	NN	I-NP
O	2575	2581	analog	analog	NN	I-NP
O	2581	2582	.	.	.	O

